EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Beyond Antibiotics: Alternative Strategies Targeting Helicobacter pylori Resistance

Amin Fath Tabar iD, Azar Nejati iD, Seyedeh Nasim Mirbahari, Mohammad Rahmanian, Ehsan Nazemalhosseini Mojarad iD, Zahra Sadeghloo iD, Hamideh Raeisi iD

Expert Reviews in Molecular Medicine · 2026 · 28

DOI: 10.1017/erm.2026.10040 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Reviews in Molecular Medicine, online erschienen am 07.04.2026. Verfasst von Amin Fath Tabar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Helicobacter pylori, Helicobacter Infections, Anti-Bacterial Agents, Drug Resistance, Bacterial. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 166 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The escalating global prevalence of antibiotic-resistant Helicobacter pylori strains has undermined conventional eradication therapies, heightening the burden of associated conditions such as gastritis, peptic ulcers and gastric malignancies. Emerging non-antibiotic alternatives, including natural and synthetic compounds, probiotics and vaccine candidates, offer potential solutions to combat these infections effectively. Natural and synthetic compounds provide promising anti- H. pylori effects, primarily through bacterial membrane disruption, urease inhibition, virulence gene suppression and biofilm prevention. in vitro and in vivo studies support the robust activity of natural agents, while synthetic counterparts demonstrate potent bactericidal and anti-adherence capabilities, though rigorous clinical validation is still required. Probiotic strains enhance eradication rates when combined with antibiotics, reduce treatment-related adverse effects, modulate gut microbiota and attenuate gastric inflammation and carcinogenesis. Vaccine development encompasses whole-cell, subunit and DNA platforms targeting key virulence factors, showing immunogenicity and protective efficacy in preclinical models, yet is limited by variable clinical translation and insufficient large-scale trials. Despite promising advancements, challenges persist, including inconsistent efficacy and a need for more rigorous human studies. Future efforts should emphasize combinatorial therapies, refined delivery systems, and thorough safety evaluations to integrate these strategies into clinical practice, fostering sustainable management of H. pylori in a post-antibiotic era.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter pyloriHelicobacter InfectionsAnti-Bacterial AgentsDrug Resistance, BacterialHumansAnimalsProbioticsBacterial Vaccines

Stichwörter der Autor:innen

Helicobacter pylorinatural compoundsprobioticssynthetic agentsvaccine

Substanzen

Anti-Bacterial AgentsBacterial Vaccines

Autor:innen und Institutionen

  • Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Skin Repair Research Center, Jordan Dermatology and Hair Transplantation Clinic, Tehran, Iran.
  • Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Student Research Committee, School of Medical Education and Learning Technologies, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

ORCID-Profile: Amin Fath Tabar, Azar Nejati, Ehsan Nazemalhosseini Mojarad, Zahra Sadeghloo, Hamideh Raeisi

Zitieren

APA

Fath Tabar, A., Nejati, A., Mirbahari, S. N., Rahmanian, M., Nazemalhosseini Mojarad, E., Sadeghloo, Z., & Raeisi, H. (2026). Beyond Antibiotics: Alternative Strategies Targeting Helicobacter pylori Resistance. Expert Reviews in Molecular Medicine, 28. https://doi.org/10.1017/erm.2026.10040

Vancouver

Fath Tabar A, Nejati A, Mirbahari SN, Rahmanian M, Nazemalhosseini Mojarad E, Sadeghloo Z, et al. Beyond Antibiotics: Alternative Strategies Targeting Helicobacter pylori Resistance. Expert Reviews in Molecular Medicine. 2026;28. doi:10.1017/erm.2026.10040

BibTeX
@article{FathTabar2026,
  author = {Fath Tabar, Amin and Nejati, Azar and Mirbahari, Seyedeh Nasim and Rahmanian, Mohammad and Nazemalhosseini Mojarad, Ehsan and Sadeghloo, Zahra and Raeisi, Hamideh},
  title = {Beyond Antibiotics: Alternative Strategies Targeting Helicobacter pylori Resistance},
  journal = {Expert Reviews in Molecular Medicine},
  year = {2026},
  volume = {28},
  doi = {10.1017/erm.2026.10040}
}
Kostenlos starten →